// App-Quantinova.ai

e20520 : Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.

Researchers

Presenter

  • Enriqueta Felip

Principal Investigators

  • Daniel Shao-Weng Tan

  • Dong-Wan Kim

  • Ranee Mehra

  • Sergey Orlov

  • Keunchil Park

  • Chong-Jen Yu

  • Tony Mok

  • Makoto Nishio

  • Giorgio V. Scagliotti

  • David R. Spigel

  • Santosh Sutradhar

  • Dajana Cesic

  • Alice Tsang Shaw

Medical Centers

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • National Cancer Centre Singapore, Singapore, Singapore

  • Fox Chase Cancer Center, Philadelphia, PA

  • Department of Thoracic Oncology, St. Petersburg State Medical University, St. Petersburg, Russia

  • National Yang-Ming University, Taipei, Taiwan

  • Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China

  • Japanese Foundation for Cancer Research, Tokyo, Japan

  • University of Turin, Turin, Italy

  • Sarah Cannon Research Institute, Nashville, TN

  • Novartis, East Hanover, NJ

  • Massachusetts General Hospital, Boston, MA

Locations

  • Taiwan

  • China

  • Japan

  • Italy

  • Singapore

  • Spain

  • United States

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ceritinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT01283516

  • NCT01685138

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved